Protagonist Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTGX and other ETFs, options, and stocks.

About PTGX

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. 

CEO
Dinesh V. Patel
CEODinesh V. Patel
Employees
132
Employees132
Headquarters
Newark, California
HeadquartersNewark, California
Founded
2006
Founded2006
Employees
132
Employees132

PTGX Key Statistics

Market cap
10.43B
Market cap10.43B
Price-Earnings ratio
140.65
Price-Earnings ratio140.65
Dividend yield
Dividend yield
Average volume
504.01K
Average volume504.01K
High today
$147.61
High today$147.61
Low today
$144.62
Low today$144.62
Open price
$146.18
Open price$146.18
Volume
319.30K
Volume319.30K
52 Week high
$148.00
52 Week high$148.00
52 Week low
$50.49
52 Week low$50.49

Stock Snapshot

As of today, Protagonist Therapeutics(PTGX) shares are valued at $145.87. The company's market cap stands at 10.43B, with a P/E ratio of 140.65.

During the trading session on 2026-08-08, Protagonist Therapeutics(PTGX) shares reached a daily high of $147.61 and a low of $144.62. At a current price of $145.87, the stock is +0.9% higher than the low and still -1.2% under the high.

Trading volume for Protagonist Therapeutics(PTGX) stock has reached 319.3K, versus its average volume of 504.01K.

Over the past 52 weeks, Protagonist Therapeutics(PTGX) stock has traded between a high of $148.00 and a low of $50.49.

Over the past 52 weeks, Protagonist Therapeutics(PTGX) stock has traded between a high of $148.00 and a low of $50.49.

PTGX News

Simply Wall St 9h
Why Protagonist Therapeutics Is Up 6.8% After Swinging to Q2 Profitability and Expanding ESOP

In August 2026, Protagonist Therapeutics reported second-quarter 2026 results showing net income of US$162.85 million, reversing a prior-year net loss and deliv...

Why Protagonist Therapeutics Is Up 6.8% After Swinging to Q2 Profitability and Expanding ESOP
TipRanks 3d
Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93

Reports Q2 revenue $213.48M, consensus $223.17M. “The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch...

TipRanks 3d
Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Analyst ratings

93%

of 14 ratings
Buy
92.9%
Hold
7.1%
Sell
0%

More PTGX News

TipRanks 3d
PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications

Protagonist Therapeutics Inc (PTGX) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...

People also own

Based on the portfolios of people who own PTGX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.